Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 2OTHER 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Rituximab 13Cyclophosphamide 12Vincristine 11Prednisone 11Doxorubicin 8Radiotherapy 6Immunohistochemistry 5VAP-cyclo protocol 4Peripheral Blood Stem Cell Transplantation 4Gene Expression Profiling 4Etoposide 4Amplified Fragment Length Polymorphism Analysis 4tositumomab I-131 3Polymerase Chain Reaction 3Microarray Analysis 3Methotrexate 3Cytarabine 3Melphalan 2Interferon-alpha 2Filgrastim 2Carmustine 2Bortezomib 2Bendamustine Hydrochloride 2thymoglobulin 1sargramostim 1pegfilgrastim 1merphos 1liposomal amphotericin B 1ixabepilone 1ibritumomab tiuxetan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Lymphoma, Follicular × denileukin diftitox × Clear all
NCT00003615 2023-06-15

Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

Eastern Cooperative Oncology Group

Phase 2 Completed
77 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡